Accueil › Cancer du poumon › Géorgie › Atlanta
Essais cliniques pour Cancer du poumon à Atlanta, GA
29 études pour Cancer du poumon recherchent des participants dans et autour de Atlanta (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Recrutement en coursPhase 3
- Northside Hospital, Atlanta
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Recrutement en coursÉtude observationnelleVolontaires sains bienvenus
- Atlanta VA Medical Center, Decatur · à 6 mi
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Recrutement en coursPhase 3
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Recrutement en coursPhase 3
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
- et 1 autres
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Recrutement en coursPhase 3
- Winship Cancer Institute of Emory University, Atlanta
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Recrutement en coursPhase 3
- Piedmont Healthcare, Inc, Atlanta
- Winship Cancer Institute, Atlanta
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Recrutement en coursPhase 3
- Piedmont Atlanta Hospital ( Site 4000), Atlanta
- Emory University School of Medicine-Phase I ( Site 0056), Atlanta
- Northside Hospital ( Site 0055), Atlanta
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Recrutement en coursPhase 2/3
- Piedmont Healthcare, Atlanta
Empowering Patients' Lung Cancer Screening Uptake (Empower LCS/Call+)
Recrutement en cours
- Emory Clinic at Old Fourth Ward, Atlanta
- Emory Clinic at Midtown, Atlanta
- Emory at Peachtree Hills - Primary Care, Atlanta
- et 19 autres
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Recrutement en coursPhase 1/2
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Recrutement en coursPhase 3
- Piedmont Cancer Institute, PC, Atlanta
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Recrutement en coursPhase 3
- Emory University School of Medicine- Grady Campus, Atlanta
- Winship Cancer Institute, Emory University, Atlanta
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Recrutement en coursPhase 1
- Emory University, Atlanta
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Recrutement en coursPhase 1/2
- Avenzo Therapeutics Recruiting Site, Atlanta
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Recrutement en coursPhase 3
- Northside Hospital Atlanta, Atlanta
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Recrutement en coursPhase 1
- Emory University - Winship Cancer Institute, Atlanta
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Recrutement en coursPhase 3
- Grady Health System, Atlanta
- Emory Proton Therapy Center, Atlanta
- Emory University Hospital Midtown, Atlanta
- et 3 autres
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Recrutement en coursPhase 1
- Xencor Investigative Site, Atlanta
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Recrutement en coursPhase 1/2
- Winship Cancer Institute - Emory University, Atlanta
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Recrutement en coursPhase 2
- Northside Hospital, Atlanta
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Recrutement en coursPhase 1/2
- Piedmont Healthcare, Atlanta
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Recrutement en coursPhase 2/3
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- et 3 autres
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
Recrutement en coursPhase 2
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
Recrutement en coursPhase 1
- Emory University Hospital/Winship Cancer Institute, Atlanta
Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer
Recrutement en coursPhase 1 précoce
- Emory University/Winship Cancer Institute, Atlanta
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
Recrutement en coursPhase 2
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
Recrutement en coursÉtude observationnelle
- Northside Hospital, Atlanta
Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer
Recrutement en coursPhase 1
- Emory University Hospital Midtown, Atlanta
- Emory University, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Recrutement en coursÉtude observationnelle
- Massive Bio SYNERGY-AI site, Atlanta
Essais pour Cancer du poumon dans d'autres villes
- Houston, TX78 études
- Boston, MA62 études
- New York City, NY60 études
- Los Angeles, CA45 études
- Washington, DC41 études
- Arlington, VA41 études
- Chicago, IL41 études
- Nashville, TN40 études
- Baltimore, MD40 études
- St. Louis, MO39 études
- Columbus, OH37 études
- Philadelphia, PA36 études
Autres études à Atlanta
- Cancer (tous types)49 études
- Cancer du poumon non à petites cellules47 études
- Cancer du sein41 études
- Myélome multiple41 études
- Cancer de la prostate33 études
- Leucémie aiguë myéloïde30 études
- Cancer de l'ovaire29 études
- Cancer colorectal29 études
- Cancer métastatique28 études
- Insuffisance cardiaque25 études
- Trouble dépressif majeur25 études
- Carcinome épidermoïde de la tête et du cou24 études
Source : ClinicalTrials.gov, données récupérées le 5 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.